


I hereby certify that this correspondence is being deposited with the US Post Office with sufficient postage as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents Washington, D.C.  
20231 on 11-6-2000

  
Timothy H. Van Dyke, Patent Attorney



RECEIVED

NOV 16 2000

TECH CENTER 1600/2900

#6Q  
11-21-00  
P2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. : 09/360,199  
Filed : 7/23/1999  
Applicants : Gauldie *et al.*  
Title : Intestinal Gene Therapy  
Group Art Unit : 1632  
Examiner : Schnizer  
Docket No. : GDI-1

To: Assistant Commissioner for Patents  
Washington, D.C. 20231


### AMENDMENT UNDER 37 C.F.R. § 1.111

In response to the Office Action mailed June 6, 2000, Applicants make the following amendments and remarks:

#### In the claims

##### Claim 1 (amended):

1. A method for delivery of a pharmaceutical composition to gastrointestinal or genitourinary cells in a recipient in need thereof which comprises

 (a) contacting the intended site of delivery of said pharmaceutical composition with an agent adequate to cause a temporary disruption of the mucosal lining covering said gastrointestinal or genitourinary cells; and

(b) concurrently or subsequent to said contacting of step (a), contacting said gastrointestinal or genitourinary cells with said pharmaceutical composition, wherein said